Kornimate/medical-research-clean huggingface dataset:
assessing different methods of anxiety care in pediatric settings

Conditions: Anxiety Disorders

Summary: this study will compare the effectiveness of delivering cognitive behavioral therapy for children with anxiety disorders through in-person contact versus through workbooks and telephone communication.

approximately 13% of adolescents aged 9 to 17 suffer from an anxiety disorder, which can cause disruptive fear, worry, or uneasiness that impairs their normal functioning. these anxiety disorders can include generalized anxiety disorder (gad), phobias, panic disorder, and obsessive-compulsive disorder (ocd), and they often co-occur with a second anxiety disorder or another mental or behavioral disorder, like depression. research on interventions such as cognitive behavioral therapy (cbt) indicates that these interventions are helpful to children who suffer from anxiety disorders, but are not always used. this study will examine the feasibility of implementing cbt for children between the ages of 8 and 13 in two different forms: through in-person contact at the pediatric primary care setting and through telephone-based contact. participants in this study will be randomly assigned to receive either cognitive behavioral therapy in primary care (cbt-pc) or therapist-assisted bibliotherapy in primary care (tab-pc). in cbt-pc, participants will have therapy administered by a child anxiety specialist, and the parents of participants will learn how to support the new skills their children learn in therapy. in tab-pc, parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cbt skills to manage their children's fears and worries. participation in this study will last 3 to 4 months, with therapy visits occuring once a week at the beginning and tapering to once every other week at the end of treatment. at pre-treatment, mid-treatment, post-treatment, and a 3-month follow-up, participants will undergo structured clinical interviews to assess their anxiety levels and the severity of their conditions.

Eligibility criteria:
inclusion criteria: * meets dsm-iv criteria for one of the following disorders: separation anxiety disorder, social phobia, generalized anxiety disorder, specific phobia, or obsessive-compulsive disorder * takes a medication and has maintained a stable dose for 3 months before baseline assessment * pediatric medical care is provided through one of the participating primary care clinics * parent and child are fluent in english exclusion criteria: * presence of a life threatening condition or a medical illness that would make participation unsafe * diagnosed with bipolar disorder i, mental retardation, or autism or has psychotic symptoms * acutely suicidal or homicidal or exhibiting dangerous behavior * parents do not consent for diagnosis and progress to be shared with their child's primary care physician

Keywords: generalized anxiety social phobia separation anxiety phobia
percutaneous tibial nerve stimulation for patients with fecal incontinence

Conditions: Fecal Incontinence

Summary: percutaneous tibial nerve stimulation is introduced as regular treatment option for fecal urge continence at the cantonal hospital st. gallen. during this introduction phase efficiency und adverse events will be monitored in this observational study.

before treatment patients will have a proctological exam, a proctoscopy, endosonography and anorectal manometry. incontinence scores (wexner, vaizey, hanley) and quality of life scores (fiql, vas) will be recorded. treatment consists of 4 phases with decreasing frequency of percutaneous tibial nerve stimulations (ptns). during phase 1 weekly stimulations of 30 mins are applied for 12 weeks. after 6 and 12 weeks incontinence scores are recorded. additionally after the end of phase 1 quality of life is measured and an anorectal manometry is preformed. phase 2 lasts for 8 weeks, with 2-3 stimulations/month phase 3 lasts for 8 weeks, with stimulations every 3 weeks phase 4 consists of one stimulation in one month. after phase 4 incontinence scores und quality of life are measured.

Eligibility criteria:
inclusion criteria: * fecal urge incontinence * conservative treatment has been performed without success exclusion criteria: * current anticoagulation treatment * sphincter defects larger than 120° * pregnancy * pace maker * implanted defibrillators * severe heart disease * existing neurological damages * disposition for strong bleeding

Keywords: fecal incontinence fecal urge incontinence percutaneous tibial nerve stimulation
evaluating fluciclovine pet in patients with biochemical recurrence of prostate cancer and a negative psma pet

Conditions: Prostate Cancer

Summary: the purpose of this prospective cohort study is to investigate the role of fluciclovine positron emission tomography (pet) in patients with biochemical recurrence of prostate cancer (bcr) and a negative prostate specific membrane antigen (psma) pet, specifically, whether fluciclovine pet can help detect local recurrence and whether the results of fluciclovine pet can change management.

primary objective: i. to evaluate the detection rate of local recurrence of prostate cancer on fluciclovine pet in patients with bcr and a negative or equivocal psma pet obtained within 30 days prior to the fluciclovine pet. secondary objectives: i. to evaluate the correct localization rate of fluciclovine pet in patients with positive scans. ii. to distinguish the detection rate by site of recurrence (local recurrence in the prostate bed, lymph node involvement, or distant metastatic disease), and stratify by psa level at the time of the scan and tumor grade iii. to evaluate the change in management based on the results of fluciclovine pet, relative to intended management based on the result of negative psma pet alone, prior to obtaining the fluciclovine pet. outline: patients will be imaged with fluciclovine pet within 30 days of the negative or equivocal psma scan. a short questionnaire inquiring about the intended management will be sent to the referring physician at two timepoints: 1) the first is at the time of screening, prior to the fluciclovine pet; and 2) the second is after the availability of the results of fluciclovine pet. change in intended management will be recorded. participants will be followed for 6 months and will be managed by their treating physician as per standard-of-care.

Eligibility criteria:
inclusion criteria: * age \>= 18 years. * participant or legally authorized representative (lar) must provide written informed consent before any study-specific procedures or interventions are performed. * patients with suspected bcr of prostate cancer after initial treatment, and a negative or equivocal psma pet, regardless of the findings on conventional imaging. initial treatment may include prostatectomy and/or radiation therapy. * psa of 0.2 ng/ml or higher within 45 days of the scan. exclusion criteria: * uncontrolled serious infection. * intercurrent illness or condition that would limit compliance with study requirements. * patients who have started any cancer treatment (systemic or radiation therapy) or who have started any supplements or herbal medications intended to treat cancer between the psma pet and axumin pet/ct scans.
stroke: reduction of physical performance post stroke. inactivity or secondary complications?

Conditions: Cerebral Stroke

Summary: the purpose of this project is to follow first-ever- acute stroke patients from onset, one, two and four years post stroke and study the effect of two different approaches of exercises implemented the first year post-stroke.

stroke is a major cause of disability and the long-term effects of stroke often lead to need of rehabilitation services. it has been shown that intensive stroke unit care and functional exercises are beneficial in the acute rehabilitation of stroke. the duration of the rehabilitation of patients with acute stroke is decreasing, leaving patients with not complete recovery at discharge in need of follow-up services. there is a general assumption that physical exercises are beneficial at all stages of stroke but it is questionable if these benefits are sustained after treatment ends. there are, to our knowledge, no longitudinal studies of non-interrupted regular physical exercises from the acute phase till one year post stroke. the purpose of this project is to follow first-ever- acute stroke patients from onset, one, two and four years post stroke. all acute stroke patients will be treated in a stroke unit and the physiotherapy treatment will be according to motor relearning programme principles with functional goals, environmental context and early mobilisation. when patients are discharged they will be block randomised and stratified according to gender and hemisphere lesion into two groups. group 1 will be offered an intensive follow-up programme, which will run four times in the post-stroke year with a total amount of 80 hours of physiotherapy. the physiotherapy treatment will be focused on physical endurance, strength and balance. group 2, or the control group, will be offered the same physiotherapy programme that is practised within the community as of now (2003) that is when the need for follow-up is considered by someone involved. the physiotherapy then given is according to specified needs e.g. walking capacity, transfers and assistive devices.

Eligibility criteria:
inclusion criteria: * first-time ever stroke * neurological signs * computer tomography confirmed stroke * voluntary participation exclusion criteria: * subarachnoid bleeding * tumour * other serious illness * brain stem or cerebellum stroke

Keywords: stroke physical therapy rehabilitation exercise longterm follow-up
bisphosphonate therapy in mona spectrum disorder

Conditions: Bone Density; Pain; Fracture

Summary: multicentric osteolysis, nodulosis and arthropathy (mona) spectrum disorder is a rare inherited progressive skeletal disorder caused by mutations in the matrix metalloproteinase 2 (mmp2) gene. treatment options are limited. the investigators reviewed the outcome of patients affected with mona and treated with intravenous bisphosphonates in the clinical center.

assessment of the patients: after informed consent had been obtained from the patients affected from mona spectrum disorder the investigators assessed the patients regarding the following characteristics: consanguinity, clinical symptoms at diseases on-set, age at on-set of symptoms and age at diagnosis, cognitive development, progression of clinical symptoms related to the diagnosis, molecular investigations, associated disorders as well as therapies besides bisphosphonate therapy. informed consent from the patients was also obtained to publish the patient's photographs. all investigations are performed according to the relevant ethical guidelines. bisphosphonate therapy: the reported patients received intravenous bisphosphonate therapy either with pamidronate (1 mg/kg/d on two consecutive days every 3 months) or zoledronate (a single dose of 0.05 mg/kg/day every 6 month). evaluation of disease progression and therapeutic success: to assess both progression of mona spectrum disorder and therapeutic success the patients were regularly evaluated clinically in 3 to 6 month intervals. clinical evaluation comprised an internal, neurological and orthopaedic status as well as a general assessment of neurocognitive function. additionally, need for oral analgesic therapy was documented. in irregular intervals, depending also on the clinical symptoms, x-rays of hand and feet were taken and a densitometry of the total body, lumbar spine and hip was performed.

Eligibility criteria:
inclusion criteria: * genetically confirmed mona spectrum disorder * treatment with bisphosphonates intravenously * positive informed consent exclusion criteria: * genetically confirmed mona spectrum disorder treated otherwise than with bisphosphonates * oral treatment with bisphosphonates in mona spectrum disorder * other inherited osteolysis syndromes than mona spectrum disorder
pain during pars plana vitrectomy with sub-tenon anesthesia

Conditions: Retinal Disease; Diabetic Retinopathy; Maculopathy

Summary: vitreoretinal surgery has evolved to less invasive procedures, and it is used to treat a wide range of diseases. so anesthesia for vitreoretinal procedures has evolved, promoting adequate analgesia while reducing risks to the patient. in the present study two types of procedures for anesthesia during vitreoretinal surgery are evaluated regarding the pain referred by the patient during the whole procedure: peribulbar anesthesia versus sub-tenon injection plus topical jelly anesthesia. through the comparative analysis of the pain scale of the two groups it is expected that the two modalities present the same anesthetic efficacy, showing that the methods used may be equivalent.


Eligibility criteria:
inclusion criteria: * patients that have the diagnosis of epiretinal membrane, macular hole, complication of diabetic retinopathy such as vitreous hemorrhage or traction retinal detachment or other vitreomacular diseases that require treatment by pars plana vitrectomy. exclusion criteria: * previous pars plana vitrectomy in the studied eye. * previous scleral buckle surgery * uncontrolled arterial hypertension * any ocular surgery performed in the studied eye in the previous three months * medical or psychological condition that preclude study adherence

Keywords: vitrectomy anesthesia retinal disease pain diabetic retinopathy maculopathy
evaluation of different strategies of pericardial drainage after aortic valvular surgery

Conditions: Pericardial Effusion; Late Cardiac Tamponade; Surgical Reintervention

Summary: the incidence of pericardial effusion and late cardiac tamponade after aortic and valvular surgery is higher than after other cardiac surgical procedures. the aim of this study is to evaluate the clinical safety and efficacy of prolonged mediastinal drainage using small, soft silastic drains (blake drain, ethicon usa) versus conventional mediastinal drainage using large chest tubes. a prospective randomized trial.

the incidence of pericardial effusion and late cardiac tamponade after aortic and valvular surgery is higher than after other cardiac surgical procedures. the aim of this study is to evaluate the clinical safety and efficacy of prolonged mediastinal drainage using small, soft silastic drains (blake drain, ethicon usa) versus conventional mediastinal drainage using large chest tubes. patients undergoing aortic and / or valvular surgery will be randomized in two groups. in group a, mediastinal drainage will be accomplished using a 28f or 32f chest tube in the anterior mediastinum and a 19f blake drain located in the posterior pericardial cavity. in group b, mediastinal drainage will be accomplished using two 28f or 32f chest tubes located in the anterior mediastinum. in both groups, conventional chest tubes will be removed on the first postoperative day, while patients in the group a will have prolonged drainage using the blake drain until output is less than 50 ml over 24 hour. patients will be followed during their postoperative course for occurrence of significant pericardial effusion as detected on routine echocardiogram and late cardiac tamponade requiring reintervention.

Eligibility criteria:
inclusion criteria: * patients aged between 18 and 90 years old, undergoing either surgery of the ascending and/or transverse aorta, or surgery of the mitral and/or aortic valves * availability for follow-up at the montreal heart institute exclusion criteria exclusion criteria: * emergency surgery * unavailability for follow-up at the montreal heart institute

Keywords: late cardiac tamponade
testing a web-based intervention for radioactive iodine symptom management (rai support) to improve health-related quality of life among differentiated thyroid cancer patients

Conditions: Thyroid Neoplasms

Summary: the goal of this clinical trial is to learn if adult patients diagnosed with differentiated thyroid cancer can easily use and benefit from an online tool aimed to provide patients with educational resources and symptom management strategies to improve their quality of life after radioactive iodine (rai) treatment. the main questions it aims to answer are: 1. can patients easily use and benefit from the rai support intervention? 2. does rai support improve health-related quality of life (overall well-being) compared to usual care? this research will help test better digital tools to support thyroid cancer survivors in managing their health after rai treatment. researchers will compare rai support to treatment as usual (a publicly available informational website about thyroid cancer) to see if rai support works to improve patients' overall well-being. participants will: 1. receive access to rai support or an informational website (treatment as usual) for four weeks. 2. use the assigned website once a week for up to four weeks. 3. complete two online questionnaires (an initial questionnaire and a final questionnaire after four weeks of using the assigned website) about symptoms related to rai treatment, mood, and confidence in managing symptoms. 4. complete an optional 60 minute virtual interview about your experiencing using the assigned website.


Eligibility criteria:
inclusion criteria: * age 18 or older (papillary or follicular carcinoma) * diagnosed with differentiated thyroid cancer * received radioactive iodine (rai) treatment less than or equal to three years ago. * mild to moderate symptoms of rai * able to provide informed consent in english * access to a computer, tablet, or smartphone with internet connectivity exclusion criteria: * a condition that precludes providing informed consent or completing study procedures (cognitive or psychiatric condition, hearing problems) as identified by the patient's physician or as assessed by a trained study team member.

Keywords: symptom burden self efficacy feasibility studies internet-based intervention pilot projects neoplasms radioactive iodine treatment iodine radioisotopes health-related quality of life informational needs
enoblituzumab plus retifanlimab or tebotelimab in head and neck cancer

Conditions: Head and Neck Cancer; Head and Neck Neoplasms; Head and Neck Squamous Cell Carcinoma

Summary: this is a phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of the head and neck.


Eligibility criteria:
inclusion criteria: * histologically proven, recurrent or metastatic squamous cell carcinoma of the head and neck (scchn) not curable by local therapy * no prior systemic therapy for scchn in the recurrent or metastatic setting (with the exception of systemic therapy completed \> 6 months prior if given as part of multimodal treatment for locally advanced disease) * primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx. patients may not have a primary tumor site of upper esophagus, salivary gland, or nasopharynx (any histology) * availability of formalin-fixed, paraffin embedded tumor specimen or contemporary biopsy for immunohistochemical evaluation of pharmacodynamic markers of interest * willing to consent for baseline and on-treatment biopsy. * performance status 0 or 1 * life expectancy of 6 months or more * adequate end organ function * at least one radiographically measurable lesion * pd-l1 expression level that is either 1. positive (combined positive score \[cps\] ≥ 1) for the retifanlimab cohort, or 2. negative (cps \< 1) for the tebotelimab cohort * results available from human papilloma virus p16 status for oropharyngeal cancer * acceptable laboratory results exclusion criteria: * disease suitable for local therapy administered with curative intent * progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced scchn * radiation or other non-systemic therapy within 2 weeks prior to the first dose of study drug * prior therapy with an anti-b7-h3, anti-pd-1, anti-pd-l1, or anti-lag-3 agent
safety and efficacy study of the neuguide device

Conditions: Pelvic Organ Prolapse

Summary: this study aims to investigate the safety, efficacy, peri and postoperative complications, and patient satisfaction of sacro-spinous ligament fixation (sslf) for the management of pelvic organ prolapse (pop). prolapse staging for all subjects in this study will be performed according to the pop-q staging system. ultrasound examinations for all subjects in this study are subjected to the surgeon need and will be performed if required by qualified personnel


Eligibility criteria:
inclusion criteria: * women ages 18-80 years old * pop-q stage iii prolapse or higher * scheduled to undergo a pop surgery and has agreed to undergo it using the neuguidetm device * patient is willing to return for follow-up evaluation and fill questionnaires as indicated on study protocol * no exclusion criteria fulfilled exclusion criteria: * diagnosis of reproductive tract anomalies * prior pelvic radiation therapy or any malignancy * inability to complete written questionnaires. * women with significant pelvic inflammatory disease (pid) history * women with known allergy to nickel or nitinol
instrumented posterolateral arthrodesis for adolescent idiopathic scoliosis

Conditions: Scoliosis; Adolescence; Arthrodesis

Summary: the study population concerns adolescent patients with idiopathic scoliosis which requires surgical management and who have a longer waiting period of 6 months. the aim of this study is to research the predictive factors of an improvement in the quality of life of adolescents who have had surgery.


Eligibility criteria:
inclusion criteria: * patient between 12 and 20 years old * scoliosis in adolescents for whom surgery has been proposed based on radiological criteria (cobb angle\> 25 ° for thoracolumbar and lumbar scoliosis,\> 35 ° for thoracic scoliosis and\> 40 ° for double major scoliosis) * patient affiliated or beneficiary of a social security scheme or attached to a beneficiary of a social security scheme * patient and legal representative having been informed and not opposing this research exclusion criteria: * patient over 20 years old * non-surgical scoliosis * refusal to participate in the study by the child or parents